The FDA last month approved Watson Pharmaceuticals' Oxytrol (oxybutynin transdermal system), a transdermal therapy to treat overactive bladder, a condition estimated to affect more than 33 million Americans. Oxytrol is a thin, flexible and clear patch that can be applied to the abdomen, hip or buttock twice weekly. Oxytrol's active ingredient, oxybutynin, has been prescribed as an oral formulation for the past 25 years.
In other news, Watson Pharmaceuticals last month completed its acquisition of the U.S. marketing rights to the Fioricet and Fiorinal product lines, both prescription treatments for migraine and tension headaches, or 178 million from Novartis. The products acquired include Fiorinal CIII (butalbital, aspirin and caffeine capsules), Fiorinal with codeine CIII, Fioricet (butalbital, acetaminophe and caffeine tablets) and Fioricet with codeine CIII.
COPYRIGHT 2003 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2003 Gale Group